Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Sep 5, 2007

166_ip_2007-09-05_86af50b4-6a72-48a7-99ce-ec20ab33bfd7.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Goldman Sachs – European Medtech and Healthcare Services Conference 2007

September 5/6, 2007

Safe Habor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE

Fresenius Group: Accomplishments H1 2007

  • -Strong operating performance in all business segments
  • -Encouraging Biotech clinical trial results
  • -Conversion into a European Company (SE)
  • -New management and reporting structure for HELIOS and VAMED
  • -Increased earnings guidance

Fresenius Group: Excellent Financial Results

S
l
a
e
s		 E
B
I
T		 N
i
t
e
n
c
o
m
e
H
1
2
0
0
7		 €
5
5
9
2
m
,		 €
7
8
0
m		 €
1
9
5
m
G
h
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 %
1
5
+		 %
2
0
+		 %
4
4
+
G
h
l
t
t
t
r
o
a
a
c
a
w
u
t
c
r
r
e
n
c
r
a
e
s
u
y		 %
1
0
+		 %
1
5
+		 %
3
9
+

Fresenius Kabi: Leading Market Positions in Infusion Therapy and Clinical Nutrition

Global production and distribution network

    • Significant growth in emerging markets
    • Focus on organic growth and on selective acquisitions
    • Market dynamics support mid-term 6-8 % organic sales growth and 16-18 % EBIT margin

Fresenius Kabi: 130 bps EBIT Margin Improvement Compared to H1 2006

€
m		 H
2
0
0
1
7		 H
2
0
0
1
6		 G
h
t
r
o
w
S
l
a
e
s		 9
8
6		 9
3
7		 5
%
(
)
%
i
7
o
r
g
a
n
c
E
B
I
T
i
E
B
I
T
m
a
r
g
n		 1
5
9
%
1
6
1		 1
3
9
%
1
4
8		 %
1
4
i
N
t
e
n
c
o
m
e		 8
7		 6
0		 %
4
5

Fresenius Kabi: 2007 Financial Outlook Fully Confirmed

Guidance

O
i
r
g
a
n
c
r
e
v
e
n
u
e
h
t
g
r
o
w		 8
%
6
–
i
E
B
I
T
m
a
r
g
n		 %
1
6
0
1
6
5
–

HELIOS Kliniken: Top-Tier Private Hospital Operator in Germany

    • Germany is Europe's largest hospital market (> € 60 bn market size)
    • Only 11% of German acute hospital beds managed by private operators
    • Significant German hospital privatization opportunity
    • HELIOS has a strong track record in hospital operations and acquisitions: targeting 15% EBITDA margin within 5 years per individual location

Source: DKG – German Hospital Federation (2004) Federal Statistical Office Germany (2004) Healthcare expenses adjusted to OECD's definition

Fresenius ProServe: 60 bps EBIT Margin Improvement Compared to H1 2006

€
m
O
i
r
g
a
n
c		 H
2
1
0
0
7		 H
2
1
0
0
6		 C
h
a
n
g
e
S
l
a
e
s		 1
0
6
9
,		 9
7
4		 %
1
0
(
)
%
i
2
o
r
g
a
n
c
E
B
I
T
i
E
B
I
T
m
a
r
g
n		 7
5
%
7
0		 6
2
%
6
4		 %
2
1
N
i
t
e
n
c
o
m
e		 3
1		 2
3		 3
%
5

Fresenius ProServe: 2007 Earnings Outlook Raised

Fresenius Biotech: Update

    • Secondary endpoints of phase II/III malignant ascites study confirm clear benefits from treatment with removab®
    • Partnering process for trifunctional antibody removab ® in North America and Japan ongoing
  • -Submission of malignant ascites dossier to EMEA end of 2007 expected
  • -2007 EBIT outlook of ~ € -50 m confirmed

Fresenius Group: Unique Opportunities in All Business Segments

F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 M
k
l
d
i
i
N
h
A
i
k
t
t
t
t
t
t
a
r
e
e
a
e
r
n
a
r
a
c
v
e
o
r
m
e
r
c
a
n
m
a
r
e
;
I
i
l
i
h
i
h
d
t
t
t
t
t
n
e
r
n
a
o
n
a
s
e
g
m
e
n
w
s
u
p
e
r
o
r
g
r
o
w
a
n
f
i
b
i
l
i
l
d
i
i
t
t
R
t
t
p
r
o
a
y
e
n
a
r
u
g
e
x
p
a
n
s
o
n
o
p
p
o
r
u
n
y
;
i
F
r
e
s
e
n
s
u
b
i
K
a		 S
i
h
l
i
f
l
d
i
i
k
t
t
t
p
e
r
o
r
g
r
o
r
e
s
n
g
r
o
m
e
a
n
g
e
m
e
r
g
n
g
m
a
r
e
s
u
w
u
i
i
d
f
l
k
d
i
i
i
i
t
t
t
t
t
p
o
s
o
n
a
n
s
u
c
c
e
s
s
u
c
o
r
e
m
a
r
e
p
r
o
u
c
n
a
v
e
s
F
i
r
e
s
e
n
u
s
S
P
r
o
e
r
v
e		 d
b
G
T
f
i
f
i
i
f
i
t
t
t
t
t
w
o
-p
r
o
n
g
e
s
r
a
e
g
y
o
e
n
e
r
o
m
s
g
n
c
a
n
e
r
m
a
n
h
i
l
i
i
i
i
h
h
l
d
i
h
i
l
t
t
t
t
t
t
t
o
s
p
a
p
r
v
a
z
a
o
n
o
p
p
o
r
u
n
y
r
o
u
g
e
a
n
g
o
s
p
a
i
d
i
j
t
t
t
t
o
p
e
r
a
o
n
s
a
n
o
s
o
r
c
n
g
p
r
o
e
c
m
a
n
a
g
e
m
e
n
p
r
e
s
e
n
c
e
u
u
i
F
r
e
s
e
n
s
u
i
h
B
t
o
e
c		 A
i
h
i
b
d
i
i
b
d
t
t
t
t
t
t
t
r
a
c
e
g
r
o
o
p
o
n
a
s
e
o
n
p
r
o
p
r
e
a
r
a
n
o
v
w
y
y
h
l
t
e
c
n
o
o
g
y

Fresenius Group: 2007 and Mid-term Outlook

2
0
0
7
l
k
t
o
o
o
u		 G
i
d
u
a
n
c
e
R
h
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 8
0
%
1
–
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 2
%
5
~
M
i
d
l
k
t
t
e
r
m
o
u
o
o
-
/
R
E
B
I
T
i
e
v
e
n
u
e
m
a
r
g
n		 /
1
5
1
5
b
2
0
1
0
y
f
b
i
f
%
R
€
1
5
E
B
I
T
1
5
e
v
e
n
u
e
s
o
n
m
a
r
g
n
o
,

Attachments

Fresenius Group: Strong Sales and EBIT Growth in all Business Segments

H
1
2
0
0
7		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
S
P
r
o
e
r
v
e
S
l
a
e
s
G
h
t
r
o
w		 \$
U
S
4
7
2
5
m
,
2
%
1
+		 €
8
9
6
m
%
5
+		 €
1
0
6
9
m
,
1
0
%
+
E
B
I
T
G
h
t
r
o
w		 \$
U
S
7
5
6
m
2
3
%
+		 €
1
5
9
m
%
1
4
+		 €
7
5
m
2
%
1
+

Fresenius Kabi: Sales H1 2007 – Fully in Line with Guidance

€
m		 H
1
2
0
0
7		 H
1
2
0
0
6		 G
h
t
r
o
w
l
S
l
T
t
o
a
a
e
s		 9
8
6		 9
3
7		 %
7
d
S
B
P
t
t
r
o
c
e
g
m
e
n
y
u
:
I
f
i
T
h
n
u
s
o
n
e
r
a
p
y		 5
2
9		 5
1
3		 4
%
C
l
i
i
l
i
i
N
t
t
n
c
a
r
o
n
u		 3
9
8		 3
6
5		 %
1
1
T
f
i
T
h
l
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 9
5		 9
5		 %
1

Fresenius Kabi: Organic Sales Growth of 7 %

S
c
o		 l
a
e
s
g
r
m
p
a
r
e		 h
H
t
o
w
d
H
t
1
o		 2
0
0
1
7
2
0
0
6		 R
e
g
€
m		 i
l
S
l
o
n
a
a
e
s		 H
1
2
0
0
7		 H
1
2
0
0
6		 G
h
t
r
o
w		 O
i
r
g
a
n
c
G
h
t
r
o
w
%
2		 G
e
r		 m
a
n
y		 2
1
3		 2
1
4		 %
0		 %
0
- E
r
u
G
e
x		 o
p
e
e
r
m
a
n
y		 4
6
1		 4
4
0		 %
5		 %
5
i
A
s
a		 i
f
i
P
a
c
c
-		 1
4
5		 1
2
2		 %
1
9		 %
2
2
%
7
+		 %
5
+		 L
i
t
a		 A
i
n
m
e
r
c
a		 6
6		 6
1		 8
%		 0
%
1
R
W
o		 1
0
1		 1
0
0		 1
%		 1
1
%
O
i
r
g
a
n
c		 F
X		 d
R
t
e
p
o
r
e		 T
t
o		 l
l
a
s
a
e
s		 9
8
6		 9
3
7		 %
5		 %
7

Fresenius Kabi: 130 bps EBIT Margin Improvement Compared to H1 2006

€
m		 H
1
2
0
0
7		 H
1
2
0
0
6		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 1
5
9
%
1
6
1		 1
3
9
8
%
1
4		 1
4
%
E
B
I
T
b
R
i
y
e
g
o
n
:
E
r
o
p
e
u
E
B
I
T
i
m
a
r
g
n		 1
4
5
2
1
5
%		 1
2
4
1
9
0
%		 %
1
7
I
i
l
t
t
n
e
r
n
a
o
n
a
E
B
I
T
i
m
a
r
g
n		 5
0
1
6
0
%		 4
6
1
6
3
%		 9
%
C
d
C
R
D
t
t
&
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 3
6
-		 3
1
-		 %
1
6
-
N
i
t
e
n
c
o
m
e		 8
7		 6
0		 4
5
%

Fresenius ProServe: Sales Growth Fully in Line with Guidance

€
m		 H
1
2
0
0
7		 H
1
2
0
0
6		 C
h
a
n
g
e		 O
i
r
g
a
n
c
S
l
a
e
s		 1
0
6
9
,		 9
7
4		 1
0
%		 2
%
S
l
b
D
i
i
i
a
e
s
y
v
s
o
n
:
i
l
O
i
H
t
t
(
)
O
S
H
E
L
I
o
s
p
a
p
e
r
a
o
n
s		 8
9
0		 7
6
7		 %
1
6		 %
3
E
i
i
S
i
f
n
g
n
e
e
r
n
g
e
r
c
e
s
o
r
v
+
h
i
l
t
(
)
h
V
A
M
E
D
P
t
o
s
p
a
s
a
r
m
a
e
c
+		 9
1
7		 2
0
*
7		 %
1
4
-		 2
%
-
O
d
i
k
E
i
i
t
r
e
r
n
a
e
n
g
n
e
e
r
n
g
b
i
u
s
n
e
s
s		 1
0
6		 8
*
1
5		 3
%
4
-		 3
%
5
-

* Including Pharmaplan

Fresenius ProServe: 60 bps EBIT Margin Improvement Compared to H1 2006

€
m		 H
2
0
0
1
7		 H
2
0
0
1
6		 G
h
t
r
o
w
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 7
5
0
%
7		 6
2
%
6
4		 2
1
%
E
B
I
T
b
D
i
i
i
s
o
n
y
v
:
H
i
l
i
t
t
o
s
p
a
o
p
e
r
a
o
n
s
i
E
B
I
T
m
a
r
g
n		 8
6
%
7
6		 5
6
%
7
3		 2
%
1
E
i
i
S
i
f
h
i
l
t
n
g
n
e
e
r
n
g
e
r
c
e
s
o
r
o
s
p
a
s
v
+
E
B
I
T
i
m
a
r
g
n		 9
5
0
%		 *
9
4
3
%		 -
C
t
t
o
r
p
o
r
a
e
c
o
s
s		 2
-		 3
-		 3
3
%

* Including Pharmaplan

Fresenius Group: Profit and Loss Statement

€
m		 Q
2
2
0
0
7		 H
1
2
0
0
7		 H
1
2
0
l
t
a
c
u
a
t
r
a
e
s		 0
7
Y
Y
o
t
t
c
o
n
s
a
n
t
r
a
e
s		 k
R
H
1
2
0
0
7
e
m
a
r
s
S
l
a
e
s		 2
8
2
5
,		 5
5
9
2
,		 1
0
%
+		 1
5
%
+		 7
%
i
h
t
o
r
g
a
n
c
g
r
o
w
E
B
I
T		 4
0
0		 7
8
0		 %
1
5
+		 %
2
0
+		 S
1
3
9
%
E
B
I
T
t
r
o
n
g
i
m
a
r
g
n
l
I
t
t
t
n
e
r
e
s
r
e
s
u		 9
0
-		 1
8
5
-		 %
5
+		 %
1
-		 I
f
R
C
G
i
t
m
p
a
c
o
a
c
q
u
i
i
f
Q
2
0
t
6
s
o
n
r
o
m
T
a
x
e
s		 1
1
1
-		 2
1
4
-		 4
%
-		 9
%
-		 3
%
b
6
t
t
t
t
a
r
a
e
a
o
x
;
d
f
i
d
2
0
0
7
t
o
m
e
n
o
g
u
N
i
t
e
n
c
o
m
e		 0
2
1		 9
1
5		 3
9
%
+		 %
4
4
+		 H
i
l.
€
1
0
6
1
6
n
c
m
:
i
t
o
n
e
m
e
e
x
p
e
n
s
e
s
-
(
)
(
)
E
P
S
f
€
p
r
e
s		 0
6
7		 1
2
7		 8
%
3
+		 %
4
2
+

Fresenius Group: Cash Flow

€
m		 Q
2
2
0
0
H
7		 2
0
0
1
7		 H
2
0
0
1
7
Y
Y
o		 R
k
H
2
0
0
1
7
e
m
a
r
s
C
h
f
l
a
s
o
w		 2
9
8		 8
2
5		 2
%
4
+		 S
i
t
r
o
n
g
e
a
r
n
n
g
s
h
t
g
r
o
w
C
h
i
W
k
i
i
l
t
a
n
g
e
n
o
r
n
g
c
a
p
a		 3
2
-		 2
9
-		 %
7
0
+
O
i
C
h
f
l
t
p
e
r
a
n
g
a
s
o
w		 2
6
6		 5
5
3		 4
8
%
+		 M
i
9
9
%
a
r
g
n
:
(
)
C
t
a
p
e
n
e
x		 1
6
5
-		 2
9
7
-		 %
3
9
-		 I
i
i
h
t
t
t
n
v
e
s
n
g
n
o
g
r
o
w
C
h
f
l
a
s
o
w
(
)
b
f
i
i
i
d
d
iv
i
d
d
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
e
n
s		 1
0
1		 2
5
6		 %
6
0
+
(
)
i
i
i
A
t
t
c
q
s
o
n
s
n
e
u		 9
9
-		 1
6
2
-		 %
9
5
+
D
i
i
d
d
v
e
n
s		 8
1
4
-		 8
8
1
-		 2
2
%
-
F
C
h
f
l
r
e
e
a
s
o
w
(
)
f
i
i
i
d
d
iv
i
d
d
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
e
n
s		 1
8
2
-		 9
4
-		 9
7
%
+

Fresenius Group: Capex and Acquisitions – Investing into Growth

Capex by Business Segment Acquisitions by Region

Fresenius Group: Debt and Interest Ratios

GS – European Medtech and Healthcare Services Conference 2007, Fresenius SE, Investor Relations © Copyright, September 5/6, 2007, Page 25

Net debt/EBITDA

Financial Calender / Contact / Basic Share Information

Financial Calender

October 31, 2007 Report on 1st - 3rd quarters 2007

Contact

Birgit Grund SVP Investor Relations Fresenius SE

e-mail:

Telephone: +49 6172 608-2485 [email protected]

Further information and current news:http://www.fresenius.com

Basic Share Information

Securities code no. 578 560 578 563Ticker symbol FRE FRE3 ISIN DE0005785604Bloomberg symbol FRE GR FRE3 GR Reuters symbol FREG.de FREG_p.de

Ordinary share Preference share

DE0005785638

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.